EP08.01-036 Low-dose EGFR-TKIs Directly Induce Maturation and Functional Activity of Human Dendritic Cells in an EGFR-independent manner

Abstract

Recently, several epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been administered concurrently with the anti-PD-1 antibody pembrolizumab in patients with EGFR mutated non-small cell lung cancer (NSCLC) in clinical trials. EGFR-TKIs with immune checkpoint inhibitors (ICIs) does have preclinical rationale in tumor-bearing syngeneic mouse models. However, the direct effect of EGFR-TKIs on APC (antigen presenting cells) such as DCs (dendritic cells) remains elusive.